Bayer reports finerenone results in FIND-CKD subgroups at ASN Kidney Week 2026
- The FSGS analysis included 215 patients, split evenly between primary and secondary disease.
- In FSGS, finerenone improved eGFR slope by 1.3 mL/min/1.73 m²/year versus placebo over 32 months and reduced UACR and UPCR by 40% and 41% at month 12.
- The IgAN analysis included 416 of the trial’s 1,584 patients; finerenone reduced UPCR by 51% at month 12 versus placebo.
- Both subgroups had a safety profile consistent with the overall trial, with few hyperkalemia-related permanent discontinuations.
FSGS subgroup
The FIND-CKD analysis included 215 patients with focal segmental glomerulosclerosis (FSGS), half with primary and half with secondary disease. Over 32 months, finerenone improved total eGFR slope by 1.3 mL/min/1.73 m²/year versus placebo (95% CI, 0.5–2.2; p<0.01). At month 12, UACR was 40% lower and UPCR 41% lower than with placebo. The kidney composite outcome of sustained eGFR decline of at least 57% or kidney failure was numerically reduced by 42%.
IgAN subgroup
Among 1,584 FIND-CKD participants, 416 had immunoglobulin A nephropathy (IgAN). Finerenone reduced UPCR by 51% versus placebo at month 12. Participants were also more likely to achieve UPCR below 500 mg/g (odds ratio 6.82) or below 300 mg/g (odds ratio 6.68). Finerenone attenuated eGFR decline and reduced several kidney injury biomarkers, but did not change plasma or serum markers of immunological disease activity.
Safety and presentation
Finerenone was well tolerated in both subgroups, with a safety profile consistent with the overall trial population and a low incidence of hyperkalemia leading to permanent discontinuation. The subgroup results were presented as late-breaking posters at ASN Kidney Week 2026 in Denver.
Source: Bayer